All Updates

All Updates

icon
Filter
Product updates
Syantra receives CE mark approval for its DXTM Breast Cancer test
Precision Medicine
Apr 18, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Apr 18, 2023

Syantra receives CE mark approval for its DXTM Breast Cancer test

Product updates

  • Genetic testing company Syantra has obtained CE marking for its flagship product, the Syantra DXTM Breast Cancer test. The CE marking will allow the company to market the blood test in the EU and other countries that recognize the designation.

  • Syantra DXTM Breast Cancer is a minimally invasive blood test that evaluates 12 gene expression biomarkers using proprietary software and machine-learning-derived algorithms to interpret the data. It detects active breast cancer in its earliest stages, making treatment easier. Syantra claims that its test may improve detection, especially for high-risk individuals, such as those with genetic predisposition, dense breasts, or diverse ethnic backgrounds, for whom mammograms may be inadequate.

  • Syantra Inc. is a biotech company that uses its flagship blood test, Syantra DXTM Breast Cancer, for the early detection of breast cancer to help optimize treatment. Syantra also uses its discovery platform, which includes the FlowPlate device, biobank, and clinical and molecular profile database, to identify novel biomarkers and drug targets. Syantra's platform focuses on drug target validation and testing using human cellular disease models to support candidate selection for clinical trials.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.